Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Daniel N. Masica"'
2
Fluoxetine in Medically Stable, Depressed Geriatric Patients
Autor: Charles M. Beasley, S.H. Hamilton, Daniel N. Masica, David J. Goldstein
Publikováno v: Journal of Clinical Psychopharmacology. 17:365-369
This study assessed the effect of fluoxetine 20 mg/day on weight loss in older patients treated for major depression in a multicenter, double-blind placebo-controlled, 6-week clinical trial. Thirty U.S. outpatient clinics affiliated with psychiatric
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e8f72e000c61eaf7ec7defe76a7f5b1
https://doi.org/10.1097/00004714-199710000-00005
Zobrazit plný text záznamu
3
The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years
Autor: Yun Wu, Elizabeth Andrews, Beth H Mann, Daniel N. Masica, Kirk Midkiff, Alicia Gilsenan, Beth Sherrill
Publikováno v: Journal of Bone and Mineral Research
The Osteosarcoma Surveillance Study, an ongoing 15-year surveillance study initiated in 2003, is a postmarketing commitment to the United States (US) Food and Drug Administration to evaluate a potential association between teriparatide, rhPTH(1–34)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bcaca1f6d02c807239cd0c25922f277
https://pubmed.ncbi.nlm.nih.gov/22991313
Zobrazit plný text záznamu
4
Fluoxetine Not Associated With Increased Violence or Aggression in Controlled Clinical Trials
Autor: John H. Heiligenstein, Daniel N. Masica, Janet H. Potvin, Emil F. Coccaro, Bruce E. Dornseif, Charles M. Beasley
Publikováno v: Annals of Clinical Psychiatry. 4:285-295
Because of interest in the possible occurrence of violent 01 aggressive behavior with serotonin-enhancing drugs, three subpools of controlled clinical trial data were evaluated: fluoxetine (n = 2615) versus placebo (n = 1377) (18 trials; depression,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18c9b9148cb1719a6a1c51ebdd490a1c
https://doi.org/10.3109/10401239209150461
Zobrazit plný text záznamu
5
Fluoxetine and Suicide
Autor: Vicki L. Thompson, John H. Heiligenstein, Daniel N. Masica, Charles M. Beasley, Alvin H. Rampey, Janet C. Bosomworth, Mary E. Sayler, Bruce E. Dornseif, Dennis J. Murphy
Publikováno v: International Clinical Psychopharmacology. 6:35-57
OBJECTIVE--A comprehensive meta-analysis of clinical trial data was performed to assess the possible association of fluoxetine and suicidality (suicidal acts and ideation). DESIGN--Retrospective analysis of pooled data from 17 double blind clinical t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8a4af49316fbc5306cb2b82099504a5
https://doi.org/10.1097/00004850-199206006-00006
Zobrazit plný text záznamu
6
Fluoxetine: no association with suicidality in obsessive-compulsive disorder
Autor: Charles M. Beasley, Janet H. Potvin, Laura A. Genduso, David E. Wheadon, Daniel N. Masica, Bruce E. Dornseif
Publikováno v: Journal of Affective Disorders. 24:1-10
Since (a) obsessive-compulsive disorder (OCD) may involve serotonergic neural transmission abnormalities also thought to be related to regulation of suicide and aggression, (b) comorbidity between OCD and depression is substantial, and (c) depression
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f4e9608d0b0b3ef576629a0e46a65e6
https://doi.org/10.1016/0165-0327(92)90054-a
Zobrazit plný text záznamu
7
Fluoxetine in tricyclic refractory major depressive disorder
Autor: Charles M. Beasley, Gregory E. Cunningham, Daniel N. Masica, Mary E. Sayler, Alan M. Weiss
Publikováno v: Journal of Affective Disorders. 20:193-200
Data regarding open-label treatment with fluoxetine following failure to respond to tricyclic antidepressants (TCAs) or intolerance of TCA side effects, suggest a response rate between 51.4% and 62.1%, depending on the definition of TCA refractorines
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e57fb98fe8f686609a592e67c989eea
https://doi.org/10.1016/0165-0327(90)90144-w
Zobrazit plný text záznamu
9
Loracarbef versus clarithromycin in children with acute otitis media with effusion
Autor: W. Manford Gooch, Jeffrey Adelglass, Don Johns, Douglas Kelsey, Daniel N. Masica, Beth C. Weinberg
Publikováno v: Clinical therapeutics. 21(4)
Two multicenter, randomized, single-masked, parallel-group studies compared loracarbef and clarithromycin with regard to efficacy, tolerability, and patient acceptance. Three hundred thirty-four children aged 6 months to 3 years with acute otitis med
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4abb7680b3c340d3ba483b2376010b7
https://pubmed.ncbi.nlm.nih.gov/10363736
Zobrazit plný text záznamu
10
Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis
Autor: Don Johns, Michael L. Zeckel, Diane S. Farlow, Daniel N. Masica
Publikováno v: Clinical therapeutics. 17(2)
Loracarbef is an oral synthetic beta-lactam antibiotic in the new carbacephem class. We conducted a multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of loracarbef 200 mg twice daily (BID) and 400 mg BID w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b069d58ad38eba388c3f5f3d25f8ef21
https://pubmed.ncbi.nlm.nih.gov/7614522
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje